ArriVent BioPharma, Inc. (AVBP)

NASDAQ: AVBP · Real-Time Price · USD

25.40

+0.20 (0.79%)

Jan 23, 2026, 9:30 AM EST - Market open

ArriVent BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	21.08	15.3	9.71	6.47	3.02
Research & Development	141.34	79	64.88	30.43	8.58
Operating Expenses	162.42	94.31	74.59	36.91	11.59
Operating Income	-162.42	-94.31	-74.59	-36.91	-11.59
Interest & Investment Income	11.02	13.82	5.26	-	-
EBT Excluding Unusual Items	-151.4	-80.49	-69.33	-36.91	-11.59
Pretax Income	-150.98	-80.49	-69.33	-36.91	-68.81
Net Income	-150.98	-80.49	-69.33	-36.91	-68.81
Net Income to Common	-150.98	-80.49	-69.33	-36.91	-68.81
Shares Outstanding (Basic)	36	31	2	1	1
Shares Outstanding (Diluted)	36	31	2	1	1
Shares Change (YoY)	52.43%	1369.88%	67.64%	79.57%	-
EPS (Basic)	-4.18	-2.56	-32.38	-28.90	-96.75
EPS (Diluted)	-4.18	-2.56	-32.38	-28.90	-96.75
EBIT	-162.42	-94.31	-74.59	-36.91	-11.59

Updated Nov 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q